How does HTA for orphan drugs differ across Europe?New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines Share XHow does HTA for orphan drugs differ across Europe?https://pharmaphorum.com/views-analysis-market-access/how-does-hta-for-orphan-drugs-differ-across-europe/
Novartis’ Kymriah okayed for funding in Scotland for lymphomaNovartis’ Kymriah has become the first CAR-T available to NHS patients across the UK after Scotland’s medicines cost-effectiveness Share XNovartis’ Kymriah okayed for funding in Scotland for lymphomahttps://pharmaphorum.com/news/novartis-kymriah-okayed-for-funding-in-scotland-for-lymphoma/
Scotland backs Pfizer’s Ibrance for breast cancerPfizer’s Ibrance has been approved for use by the NHS in Scotland as a second-line treatment for advanced Share XScotland backs Pfizer’s Ibrance for breast cancerhttps://pharmaphorum.com/news/scotland-backs-pfizers-ibrance-for-breast-cancer/
SMC approves medicines for breast cancer, skin cancer, schizophreniaThe Scottish Medicines Consortium (SMC) has given approvals to Lilly’s breast cancer drug Verzenios, Merck’s Keytruda and Allergan’s Share XSMC approves medicines for breast cancer, skin cancer, schizophreniahttps://pharmaphorum.com/news/smc-approves-medicines-for-breast-cancer-skin-cancer-schizophrenia/
Keeping up the PACE at the Scottish Medicines Consortium (SMC)There are many ways that patient centricity could be delivered when doing a health technology assessment (HTA). The Share XKeeping up the PACE at the Scottish Medicines Consortium (SMC)https://pharmaphorum.com/views-analysis-market-access/keeping-up-the-pace-at-the-scottish-medicines-consortium-smc/
The shadow of Brexit on speed of accessNo-one can miss the ongoing saga that is the UK’s exit from the European Union (EU). The uncertainties Share XThe shadow of Brexit on speed of accesshttps://pharmaphorum.com/views-analysis-market-access/the-shadow-of-brexit-on-speed-of-access/
Scotland says no to Yescarta, but backs KymriahScotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types Share XScotland says no to Yescarta, but backs Kymriahhttps://pharmaphorum.com/news/scotland-says-no-to-yescarta-but-backs-kymriah/
Access to new medicines in Scotland: a perennial issueAccess to new medicines in Scotland – just as it would seem is the case everywhere – is Share XAccess to new medicines in Scotland: a perennial issuehttps://pharmaphorum.com/views-and-analysis/access-to-new-medicines-in-scotland-a-perennial-issue/
Scotland decision helps Opdivo in UK market access pictureThe last 18 months has seen groundbreaking cancer immunotherapies, led by BMS’s Opdivo and Merck Sharp & Dohme’s Share XScotland decision helps Opdivo in UK market access picturehttps://pharmaphorum.com/news/scotland-decision-helps-opdivo-uk-market-access-picture/
